BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, Smyth EC, Cunningham D, Allum WH, Mason RC. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014;32:2983-2990. [PMID: 25071104 DOI: 10.1200/jco.2014.55.9070] [Cited by in Crossref: 129] [Cited by in F6Publishing: 70] [Article Influence: 18.4] [Reference Citation Analysis]
Number Citing Articles
1 Hernandez JM, Beylergil V, Goldman DA, van Beek E, Gonen M, Tang L, Downey R, Rizk N, Shah M, Strong V, Janjigian Y, Schöder H, Coit DG. Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. Ann Surg 2018;267:898-904. [PMID: 28767564 DOI: 10.1097/SLA.0000000000002306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Biondi A, Lirosi MC, D’Ugo D, Fico V, Ricci R, Santullo F, Rizzuto A, Cananzi FC, Persiani R. Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives. World J Gastrointest Oncol 2015; 7(12): 389-400 [PMID: 26690252 DOI: 10.4251/wjgo.v7.i12.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
3 Ferrer-Torres D, Nancarrow DJ, Kuick R, Thomas DG, Nadal E, Lin J, Chang AC, Reddy RM, Orringer MB, Taylor JM, Wang TD, Beer DG. Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas. Oncotarget 2016;7:54867-82. [PMID: 27363029 DOI: 10.18632/oncotarget.10253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Tong Y, Zhu Y, Zhao Y, Shan Z, Zhang J, Liu D. Tumor Regression Grade Predicts Survival in Locally Advanced Gastric Adenocarcinoma Patients with Lymph Node Metastasis. Gastroenterol Res Pract 2020;2020:3435673. [PMID: 32733550 DOI: 10.1155/2020/3435673] [Reference Citation Analysis]
5 Xu H, Zhang L, Miao J, Liu S, Liu H, Jia T, Zhang Q. Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study. World J Surg Oncol 2020;18:144. [PMID: 32593312 DOI: 10.1186/s12957-020-01917-5] [Reference Citation Analysis]
6 Tu CC, Hsu PK, Chien LI, Liu WC, Huang CS, Hsieh CC, Hsu HS, Wu YC. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery. BMC Cancer 2017;17:62. [PMID: 28103913 DOI: 10.1186/s12885-017-3063-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
7 Noble F, Lloyd MA, Turkington R, Griffiths E, O'Donovan M, O'Neill JR, Mercer S, Parsons SL, Fitzgerald RC, Underwood TJ; OCCAMS consortium. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. Br J Surg 2017;104:1816-28. [PMID: 28944954 DOI: 10.1002/bjs.10627] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
8 Koch C, Reitz C, Schreckenbach T, Eichler K, Filmann N, Al-Batran SE, Götze T, Zeuzem S, Bechstein WO, Kraus T, Bojunga J, Düx M, Trojan J, Blumenstein I. Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma. PLoS One 2019;14:e0223613. [PMID: 31639132 DOI: 10.1371/journal.pone.0223613] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
9 Shen LY, Fan MY, Dong B, Yan WP, Chen KN. Increased HOXC6 expression predicts chemotherapy sensitivity in patients with esophageal squamous cell carcinoma. Oncol Lett 2017;14:4835-40. [PMID: 29085488 DOI: 10.3892/ol.2017.6772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Giampieri R, Del Prete M, Cantini L, Baleani MG, Bittoni A, Maccaroni E, Berardi R. Optimal management of resected gastric cancer. Cancer Manag Res 2018;10:1605-18. [PMID: 29950898 DOI: 10.2147/CMAR.S151552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Markar SR, Gronnier C, Pasquer A, Duhamel A, Behal H, Théreaux J, Gagnière J, Lebreton G, Brigand C, Renaud F, Piessen G, Meunier B, Collet D, Mariette C; FREGAT Working Group—FRENCH—AFC. Discrepancy Between Clinical and Pathologic Nodal Status of Esophageal Cancer and Impact on Prognosis and Therapeutic Strategy. Ann Surg Oncol 2017;24:3911-20. [PMID: 28948524 DOI: 10.1245/s10434-017-6088-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tong Y, Zhu Y, Zhao Y, Jiang C, Wang W, Shan Z, Sun F, Liu D, Zhang J. CA724 Predicts Tumor Regression Grade in Locally Advanced Gastric Cancer Patients with Neoadjuvant Chemotherapy. J Cancer 2021;12:6465-72. [PMID: 34659537 DOI: 10.7150/jca.60694] [Reference Citation Analysis]
13 Tong Y, Zhu Y, Zhao Y, Shan Z, Liu D, Zhang J. Evaluation and Comparison of Predictive Value of Tumor Regression Grades according to Mandard and Becker in Locally Advanced Gastric Adenocarcinoma. Cancer Res Treat 2021;53:112-22. [PMID: 32777876 DOI: 10.4143/crt.2020.516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Lemini R, Díaz Vico T, Trumbull DA, Attwood K, Spaulding AC, Elli EF, Colibaseanu DT, Kukar M, Gabriel E. Prognostic models for stage I-III esophageal cancer: a comparison between existing calculators. J Gastrointest Oncol 2021;12:1963-72. [PMID: 34790364 DOI: 10.21037/jgo-20-337] [Reference Citation Analysis]
15 Tian Y, Wang J, Qiao X, Zhang J, Li Y, Fan L, Zhang Z, Zhao X, Tan B, Wang D, Yang P, Zhao Q. Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction. Front Oncol 2021;11:756440. [PMID: 34858829 DOI: 10.3389/fonc.2021.756440] [Reference Citation Analysis]
16 Giacopuzzi S, Bencivenga M, Weindelmayer J, Verlato G, de Manzoni G. Western strategy for EGJ carcinoma. Gastric Cancer. 2017;20:60-68. [PMID: 28039533 DOI: 10.1007/s10120-016-0685-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
17 Saigí M, Oliva M, Aliste L, Calvo M, Hormigo G, Serra Ò, Boladeras A, Farran L, Robles J, Creus G, Paúles MJ, Gornals JB, de Lama E, Borràs JM, Sala N, Galán M. Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre. PLoS One 2017;12:e0184737. [PMID: 28931046 DOI: 10.1371/journal.pone.0184737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
18 Lu B, Lu C, Sun Z, Qu C, Chen J, Hua Z, Tong R, Zhang J. Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. J Int Med Res 2019;47:2207-14. [PMID: 30991863 DOI: 10.1177/0300060519827191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Bott RK, George G, McEwen R, Zylstra J, Knight WRC, Baker CR, Kelly M, Griffin N, McAddy N, Maisey N, Van Hemelrijck M, Gossage JA, Lagergren J, Davies AR. Predicting response to neoadjuvant chemotherapy in patients with oesophageal adenocarcinoma. Acta Oncol 2021;:1-8. [PMID: 34613874 DOI: 10.1080/0284186X.2021.1986228] [Reference Citation Analysis]
20 Knight WRC, Yip C, Wulaningsih W, Jacques A, Griffin N, Zylstra J, Van Hemelrijck M, Maisey N, Gaya A, Baker CR, Kelly M, Gossage JA, Lagergren J, Landau D, Goh V, Davies AR, Ngan S, Qureshi A, Deere H, Green M, Chang F, Mahadeva U, Gill-Barman B, George S, Dunn J, Zeki S, Meenan J, Hynes O, Tham G, Iezzi C; Guy's and St Thomas' Oesophago‐Gastric Research Group. Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. BJS Open 2019;3:767-76. [PMID: 31832583 DOI: 10.1002/bjs5.50211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Jiang D, Wang H, Song Q, Wang H, Wang Q, Tan L, Hou Y. Comparison of the prognostic difference between ypTNM and equivalent pTNM stages in esophageal squamous cell carcinoma based on the 8th edition of AJCC classification. J Cancer 2020;11:1808-15. [PMID: 32194792 DOI: 10.7150/jca.34567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Hegemann NS, Koepple R, Walter F, Boeckle D, Fendler WP, Angele MK, Boeck S, Belka C, Roeder F. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival. Strahlenther Onkol 2018;194:435-43. [PMID: 29349603 DOI: 10.1007/s00066-018-1261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Li J, Zhao Q, Ge X, Song Y, Tian Y, Wang S, Liu M, Qiao X. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis. BMC Surg 2021;21:137. [PMID: 33731072 DOI: 10.1186/s12893-021-01136-z] [Reference Citation Analysis]
24 Nangraj AS, Selvaraj G, Kaliamurthi S, Kaushik AC, Cho WC, Wei DQ. Integrated PPI- and WGCNA-Retrieval of Hub Gene Signatures Shared Between Barrett's Esophagus and Esophageal Adenocarcinoma. Front Pharmacol 2020;11:881. [PMID: 32903837 DOI: 10.3389/fphar.2020.00881] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
25 Lieto E, Auricchio A, Tirino G, Pompella L, Panarese I, Del Sorbo G, Ferraraccio F, De Vita F, Galizia G, Cardella F. Naples Prognostic Score Predicts Tumor Regression Grade in Resectable Gastric Cancer Treated with Preoperative Chemotherapy. Cancers (Basel) 2021;13:4676. [PMID: 34572903 DOI: 10.3390/cancers13184676] [Reference Citation Analysis]
26 Ronellenfitsch U, Klose J, Kleeff J. Multimodal Therapy of Upper Gastrointestinal Malignancies. Cancers (Basel) 2021;13:793. [PMID: 33672858 DOI: 10.3390/cancers13040793] [Reference Citation Analysis]
27 Smyth EC, Nyamundanda G, Cunningham D, Fontana E, Ragulan C, Tan IB, Lin SJ, Wotherspoon A, Nankivell M, Fassan M, Lampis A, Hahne JC, Davies AR, Lagergren J, Gossage JA, Maisey N, Green M, Zylstra JL, Allum WH, Langley RE, Tan P, Valeri N, Sadanandam A. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Ann Oncol. 2018;29:2356-2362. [PMID: 30481267 DOI: 10.1093/annonc/mdy407] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
28 Piro G, Giacopuzzi S, Bencivenga M, Carbone C, Verlato G, Frizziero M, Zanotto M, Mina MM, Merz V, Santoro R, Zanoni A, De Manzoni G, Tortora G, Melisi D. TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. Br J Cancer 2015;113:878-85. [PMID: 26291056 DOI: 10.1038/bjc.2015.283] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
29 Bhangoo RS, DeWees TA, Yu NY, Ding JX, Liu C, Golafshar MA, Rule WG, Vora SA, Ross HJ, Ahn DH, Beamer SE, Jaroszewski DE, Hallemeier CL, Liu W, Ashman JB, Sio TT. Acute Toxicities and Short-Term Patient Outcomes After Intensity-Modulated Proton Beam Radiation Therapy or Intensity-Modulated Photon Radiation Therapy for Esophageal Carcinoma: A Mayo Clinic Experience. Adv Radiat Oncol 2020;5:871-9. [PMID: 33083649 DOI: 10.1016/j.adro.2020.04.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 McNamara MJ, Rybicki LA, Sohal D, Allende DS, Videtic GM, Rodriguez CP, Stephans KL, Murthy SC, Raja S, Raymond D, Ives DI, Bodmann JW, Adelstein DJ. The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen. J Gastrointest Oncol 2016;7:196-205. [PMID: 27034786 DOI: 10.3978/j.issn.2078-6891.2015.097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Shi Q, Shen L, Dong B, Fu H, Kang X, Dai L, Yang Y, Yan W, Chen KN. Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy. Thorac Cancer 2018;9:836-46. [PMID: 29757528 DOI: 10.1111/1759-7714.12758] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
32 Kosovec JE, Zaidi AH, Pounardjian TS, Jobe BA. The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy. Front Oncol 2018;8:610. [PMID: 30619750 DOI: 10.3389/fonc.2018.00610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
33 Martin-Romano P, Sola JJ, Diaz-Gonzalez JA, Chopitea A, Iragorri Y, Martínez-Regueira F, Ponz-Sarvise M, Arbea L, Subtil JC, Cano D, Ceniceros L, Legaspi J, Hernandez JL, Rodríguez J. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer. Br J Cancer 2016;115:655-63. [PMID: 27537382 DOI: 10.1038/bjc.2016.252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
34 Schoppmann SF, Kristo I, Riegler M. Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer? Transl Gastroenterol Hepatol 2018;3:101. [PMID: 30701208 DOI: 10.21037/tgh.2018.11.07] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Alexandre L, Clark AB, Walton S, Lewis MP, Kumar B, Cheong EC, Warren H, Kadirkamanathan SS, Parsons SL, Dresner SM, Sims E, Jones M, Hammond M, Flather M, Loke YK, Swart AM, Hart AR. Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT-ROC feasibility study. BJS Open 2020;4:59-70. [PMID: 32011825 DOI: 10.1002/bjs5.50239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Findlay JM, Castro-Giner F, Makino S, Rayner E, Kartsonaki C, Cross W, Kovac M, Ulahannan D, Palles C, Gillies RS, MacGregor TP, Church D, Maynard ND, Buffa F, Cazier JB, Graham TA, Wang LM, Sharma RA, Middleton M, Tomlinson I. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun 2016;7:11111. [PMID: 27045317 DOI: 10.1038/ncomms11111] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
37 Zhao J, Wang G, Jiang ZW, Jiang CW, Liu J, Xia CC, Li JS. Patients Administered Neoadjuvant Chemotherapy Could be Enrolled into an Enhanced Recovery after Surgery Program for Locally Advanced Gastric Cancer. Chin Med J (Engl) 2018;131:413-9. [PMID: 29451145 DOI: 10.4103/0366-6999.225047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Orditura M, Galizia G, Lieto E, De Vita F, Ciardiello F. Treatment of esophagogastric junction carcinoma: An unsolved debate. World J Gastroenterol 2015; 21(15): 4427-4431 [PMID: 25914451 DOI: 10.3748/wjg.v21.i15.4427] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
39 Funt SA, Chapman PB. The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. Clin Cancer Res 2016;22:2323-8. [PMID: 26842238 DOI: 10.1158/1078-0432.CCR-15-1961] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 Que SJ, Chen QY, Qing-Zhong, Liu ZY, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng HL, Li P, Zheng CH, Huang CM, Xie JW. Application of preoperative artificial neural network based on blood biomarkers and clinicopathological parameters for predicting long-term survival of patients with gastric cancer. World J Gastroenterol 2019; 25(43): 6451-6464 [PMID: 31798281 DOI: 10.3748/wjg.v25.i43.6451] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
41 Wang X, Zhao L, Liu H, Zhong D, Liu W, Shan G, Dong F, Gao W, Bai C, Li X. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer 2016;114:1326-33. [PMID: 27172250 DOI: 10.1038/bjc.2016.126] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
42 Liou DZ, Backhus LM, Lui NS, Shrager JB, Berry MF. Induction therapy for locally advanced distal esophageal adenocarcinoma: Is radiation Always necessary? J Thorac Cardiovasc Surg 2018;155:2697-707. [PMID: 29530567 DOI: 10.1016/j.jtcvs.2017.12.136] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Li Z, Wang Y, Ying X, Shan F, Wu Z, Zhang L, Li S, Jia Y, Ren H, Ji J. Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis. BMC Cancer 2019;19:80. [PMID: 30651085 DOI: 10.1186/s12885-019-5283-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lagarde SM, Phillips AW, Navidi M, Disep B, Immanuel A, Griffin SM. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. Br J Cancer. 2015;113:1427-1433. [PMID: 26554656 DOI: 10.1038/bjc.2015.354] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
45 Parkinson C, Foley K, Whybra P, Hills R, Roberts A, Marshall C, Staffurth J, Spezi E. Evaluation of prognostic models developed using standardised image features from different PET automated segmentation methods. EJNMMI Res 2018;8:29. [PMID: 29644499 DOI: 10.1186/s13550-018-0379-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
46 Rice TW, Ishwaran H, Kelsen DP, Hofstetter WL, Apperson-Hansen C, Blackstone EH; Worldwide Esophageal Cancer Collaboration Investigators. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29:906-912. [PMID: 27905170 DOI: 10.1111/dote.12538] [Cited by in Crossref: 34] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
47 Simoni N, Rossi G, Benetti G, Zuffante M, Micera R, Pavarana M, Guariglia S, Zivelonghi E, Mengardo V, Weindelmayer J, Giacopuzzi S, de Manzoni G, Cavedon C, Mazzarotto R. 18F-FDG PET/CT Metrics Are Correlated to the Pathological Response in Esophageal Cancer Patients Treated With Induction Chemotherapy Followed by Neoadjuvant Chemo-Radiotherapy. Front Oncol. 2020;10:599907. [PMID: 33330097 DOI: 10.3389/fonc.2020.599907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Taylor Ripley R, Surman DR, Diggs LP, Trepel JB, Lee MJ, Ryan J, Davis JL, Steinberg SM, Hernandez JM, Hoang C, Kenney CM, Bond CD, Kunst TF, Letai A, Schrump DS. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy. BMC Gastroenterol 2018;18:94. [PMID: 29933761 DOI: 10.1186/s12876-018-0823-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
49 Thomaschewski M, Hummel R, Petrova E, Knief J, Wellner UF, Keck T, Bausch D. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. World J Gastroenterol 2018; 24(13): 1429-1439 [PMID: 29632424 DOI: 10.3748/wjg.v24.i13.1429] [Reference Citation Analysis]
50 Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017;18:69. [PMID: 29143893 DOI: 10.1007/s11864-017-0510-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
51 Lin D, Ma L, Ye T, Pan Y, Shao L, Song Z, Jiang S, Chen H, Xiang J. Results of neoadjuvant therapy followed by esophagectomy for patients with locally advanced thoracic esophageal squamous cell carcinoma. J Thorac Dis 2017;9:318-26. [PMID: 28275480 DOI: 10.21037/jtd.2017.02.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
52 Zeng M, Aguila FN, Patel T, Knapp M, Zhu XQ, Chen XL, Price PD. Intensity modulated radiation therapy with simultaneous integrated boost based dose escalation on neoadjuvant chemoradiation therapy for locally advanced distal esophageal adenocarcinoma. World J Gastrointest Oncol 2016; 8(5): 474-480 [PMID: 27190587 DOI: 10.4251/wjgo.v8.i5.474] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
53 McNamara MJ, Adelstein DJ, Allende DS, Bodmann JW, Ives DI, Murthy SC, Raymond D, Raja S, Rodriguez CP, Sohal D, Stephans KL, Videtic GMM, Rybicki LA. Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes. J Gastrointest Cancer 2017;48:181-9. [PMID: 27734205 DOI: 10.1007/s12029-016-9881-x] [Reference Citation Analysis]
54 Carder C, Fielding P, Roberts A, Foley K. Discordant nodal staging identifies intermediate-risk group for overall survival in patients with cT3 oesophageal adenocarcinoma. Eur Radiol 2020;30:3429-37. [PMID: 32055952 DOI: 10.1007/s00330-019-06642-6] [Reference Citation Analysis]
55 Li S, Li B, Wang J, Zhang D, Liu Z, Zhang Z, Zhang W, Wang Y, Bai D, Guan J. Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction. Oncol Res. 2017;25:93-97. [PMID: 28081737 DOI: 10.3727/096504016x14719078133564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
56 Lerttanatum N, Tharavej C, Chongpison Y, Sanpavat A. Comparison of tumor regression grading system in locally advanced esophageal squamous cell carcinoma after preoperative radio-chemotherapy to determine the most accurate system predicting prognosis. J Gastrointest Oncol 2019;10:276-82. [PMID: 31032095 DOI: 10.21037/jgo.2018.12.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
57 Gu J, Zhang J, Zheng L, Ajani JA, Wu X, Ye Y. Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. Sci Rep. 2018;8:14006. [PMID: 30228315 DOI: 10.1038/s41598-018-32282-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
58 Martin-Romano P, Solans BP, Cano D, Subtil JC, Chopitea A, Arbea L, Lozano MD, Castanon E, Baraibar I, Salas D, Hernandez-Lizoain JL, Trocóniz IF, Rodriguez J. Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. PLoS One 2019;14:e0215970. [PMID: 31071108 DOI: 10.1371/journal.pone.0215970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
59 Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. J Cancer 2019;10:1097-102. [PMID: 30854116 DOI: 10.7150/jca.29353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
60 Conway AM, Salih Z, Papaxoinis G, Fletcher K, Weaver J, Patrao A, Noble R, Stamatopoulou S, Owen-Holt V, Mansoor W. Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. Med Oncol 2017;34:116. [PMID: 28500616 DOI: 10.1007/s12032-017-0976-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
61 Christensen JF, Simonsen C, Banck-Petersen A, Thorsen-Streit S, Herrstedt A, Djurhuus SS, Egeland C, Mortensen CE, Kofoed SC, Kristensen TS, Garbyal RS, Pedersen BK, Svendsen LB, Højman P, de Heer P. Safety and feasibility of preoperative exercise training during neoadjuvant treatment before surgery for adenocarcinoma of the gastro-oesophageal junction. BJS Open 2019;3:74-84. [PMID: 30734018 DOI: 10.1002/bjs5.50110] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
62 Han J, Zhou Y, Zheng Y, Wang M, Cui J, Chen P, Yu J. Positive Effect of Higher Adult Body Mass Index on Overall Survival of Digestive System Cancers Except Pancreatic Cancer: A Systematic Review and Meta-Analysis. Biomed Res Int 2017;2017:1049602. [PMID: 28948163 DOI: 10.1155/2017/1049602] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
63 Wu M, Wang Y, Yang D, Gong Y, Rao F, Liu R, Danna Y, Li J, Fan J, Chen J, Zhang W, Zhan Q. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. EBioMedicine 2019;41:244-55. [PMID: 30876762 DOI: 10.1016/j.ebiom.2019.02.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
64 Myers AL, Lin L, Nancarrow DJ, Wang Z, Ferrer-Torres D, Thomas DG, Orringer MB, Lin J, Reddy RM, Beer DG, Chang AC. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma. Oncotarget 2015;6:25897-916. [PMID: 26317790 DOI: 10.18632/oncotarget.4532] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
65 Levenson G, Voron T, Paye F, Balladur P, Debove C, Chafai N, De Dios AG, Lefevre JH, Parc Y. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma. Surgery 2021;170:1711-7. [PMID: 34561115 DOI: 10.1016/j.surg.2021.08.021] [Reference Citation Analysis]
66 Ji KSY, Thomas SM, Roman SA, Czito B, Anderson KL Jr, Frakes J, Adam MA, Sosa JA, Robinson TJ. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. J Gastrointest Surg. 2019;23:885-894. [PMID: 30374818 DOI: 10.1007/s11605-018-4007-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
67 Murugaesu N, Wilson GA, Birkbak NJ, Watkins T, McGranahan N, Kumar S, Abbassi-Ghadi N, Salm M, Mitter R, Horswell S. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 2015;5:821-831. [PMID: 26003801 DOI: 10.1158/2159-8290.cd-15-0412] [Cited by in Crossref: 158] [Cited by in F6Publishing: 102] [Article Influence: 22.6] [Reference Citation Analysis]
68 Wang W, Peng S, Wu H, Luo Y, Yuan F, Lin Z, Cheng G, Chen S. Association of tumor downstaging after neoadjuvant chemotherapy with survival in patients with locally advanced nasopharyngeal carcinoma: a retrospective cohort study. J Cancer Res Clin Oncol 2021;147:2913-22. [PMID: 34160678 DOI: 10.1007/s00432-021-03690-8] [Reference Citation Analysis]
69 Hu SB, Liu CH, Wang X, Dong YW, Zhao L, Liu HF, Cao Y, Zhong DR, Liu W, Li YL, Gao WS, Bai CM, Shang ZH, Li XY. Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer. World J Surg Oncol 2019;17:3. [PMID: 30606195 DOI: 10.1186/s12957-018-1534-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
70 Zheng Y, Liu X, Zhang R, Wang Z, Sun H, Qin J, Liu S, Li Y. Neoadjuvant chemotherapy with or without neoadjuvant radiotherapy compared with neoadjuvant chemoradiotherapy for esophageal cancer. J Thorac Dis 2018;10:4715-23. [PMID: 30233843 DOI: 10.21037/jtd.2018.07.124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Stebbing J, Shah K, Lit LC, Gagliano T, Ditsiou A, Wang T, Wendler F, Simon T, Szabó KS, O'Hanlon T, Dean M, Roslani AC, Cheah SH, Lee SC, Giamas G. LMTK3 confers chemo-resistance in breast cancer. Oncogene 2018;37:3113-30. [PMID: 29540829 DOI: 10.1038/s41388-018-0197-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
72 Findlay JM, Dickson E, Fiorani C, Bradley KM, Mukherjee S, Gillies RS, Maynard ND, Middleton MR. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence. Eur Radiol 2019;29:6717-27. [PMID: 31278574 DOI: 10.1007/s00330-019-06310-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
73 Kamarajah SK, Navidi M, Wahed S, Immanuel A, Hayes N, Griffin SM, Phillips AW. Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction. Ann Surg Oncol 2020;27:3182-92. [PMID: 32201923 DOI: 10.1245/s10434-020-08358-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Zhao Z, Zhang Y, Wang X, Geng X, Zhu L, Li M. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. Cancer Med 2020;9:5881-8. [PMID: 32627960 DOI: 10.1002/cam4.3273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
75 Huang H, Fang W, Lin Y, Zheng Z, Wang Z, Chen X, Yu K, Lu G. Predictive Model for Overall Survival and Cancer-Specific Survival in Patients with Esophageal Adenocarcinoma. J Oncol 2021;2021:4138575. [PMID: 34567114 DOI: 10.1155/2021/4138575] [Reference Citation Analysis]
76 Boucher ANC, Ng O, Saunders JH, Acheson AG, Parsons SL. Anaemia and its effects on tumour regression grade and survival following chemotherapy in adenocarcinoma of the oesophagus. J Gastrointest Oncol 2018;9:797-805. [PMID: 30505578 DOI: 10.21037/jgo.2018.06.05] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Lee SM, Katz MH, Liu L, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, Rashid A, Wang H. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival. Am J Surg Pathol 2016;40:1653-60. [PMID: 27631521 DOI: 10.1097/PAS.0000000000000738] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 11.2] [Reference Citation Analysis]
78 Bradley NA, Wilson C, Graham J, Evans J, Fullarton G, Mackay CK, Craig C, McIntosh D, MacDonald A, Grose D, Forshaw M. The downstaging approach to irresectable oesophageal and gastric cancer: a single centre experience. J Gastrointest Oncol 2019;10:499-505. [PMID: 31183200 DOI: 10.21037/jgo.2019.01.32] [Reference Citation Analysis]